Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia

Clin Infect Dis. 2007 Dec 1;45(11):1527-9. doi: 10.1086/523011.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aged
  • Cost-Benefit Analysis
  • Herpes Zoster / prevention & control*
  • Herpes Zoster Vaccine / economics*
  • Herpes Zoster Vaccine / immunology*
  • Humans
  • Neuralgia, Postherpetic / economics
  • Neuralgia, Postherpetic / prevention & control*

Substances

  • Herpes Zoster Vaccine